{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-025823","form_type":"8-K","ticker":"BAX","cik":"0000010456","company_name":"BAXTER INTERNATIONAL INC","filed_at":"2023-07-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.002788+00:00","generated_at":"2026-06-12T23:37:31.438585+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Baxter Q2 revenue beats; GAAP loss; adjusted EPS down 24%; KidneyCare spinoff named Vantive","bullets":["Q2 continuing ops revenue $3.71B, +3% reported (+4% constant currency), above guidance.","GAAP EPS from continuing ops ($0.39); total GAAP EPS ($0.28); adjusted total EPS $0.66, -24% YoY.","FY23 adjusted EPS from continuing ops guidance: $2.49-$2.57 (BPS not sold) or $2.54-$2.62 (BPS sold Sept 30).","Kidney Care spinoff to be named Vantive; Chris Toth named CEO; expected by July 2024.","Definitive agreement to divest BioPharma Solutions to Advent/Warburg Pincus; closing expected H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-025823","json":"https://secwatch.observer/filing/0001628280-23-025823.json","markdown":"https://secwatch.observer/filing/0001628280-23-025823.md","text":"https://secwatch.observer/filing/0001628280-23-025823.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/10456/000162828023025823/0001628280-23-025823-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/10456/000162828023025823/bax-20230727.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T23:37:31.438585+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5ea68b145a78733e74e96233a986bf597e2128a6","claim":"BAXTER INTERNATIONAL INC reported the second quarter of 2023 results: revenue $3.71 billion, net income ($141 million), EPS ($0.28) per diluted share.","evidence_excerpt":"an effort to drive greater value for our stakeholders.” Second-Quarter Financial Results Worldwide sales from continuing operations in the second quarter totaled approximately $3.71 billion and sales from discontinued operations totaled $142 million in the quarter. This performance represented an increase of 3% on a reported basis and 4% on a constant currency","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/10456/000162828023025823/0001628280-23-025823-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter of 2023"},{"label":"Revenue","value":"$3.71 billion"},{"label":"Net income","value":"($141 million)"},{"label":"EPS","value":"($0.28) per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}